Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Reilly

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Science Advances|July 20, 2022
Transplanted organoids empower human preclinical assessment of drug candidate for the clinicAmy D Westerling-Bui, Eva Maria Fast, Thomas W Soare, et al.
Blood|October 27, 2007
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromesGuillermo Garcia-Manero, Hui Yang, Carlos Bueso-Ramos, et al.
Cancer Research|February 11, 2010
MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptorBo-Sheng Pan, Grace K Y Chan, Melissa Chenard, et al.
Journal of Medicinal Chemistry|February 6, 2013
Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-MetAlan B Northrup, Matthew H Katcher, Michael D Altman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaksDiane Palmieri, Paul R Lockman, Fancy C Thomas, et al.
Journal of Medicinal Chemistry|May 26, 2011
Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancerJason D Katz, James P Jewell, David J Guerin, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Science Advances|July 20, 2022
Transplanted organoids empower human preclinical assessment of drug candidate for the clinicAmy D Westerling-Bui, Eva Maria Fast, Thomas W Soare, et al.
Blood|October 27, 2007
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromesGuillermo Garcia-Manero, Hui Yang, Carlos Bueso-Ramos, et al.
Cancer Research|February 11, 2010
MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptorBo-Sheng Pan, Grace K Y Chan, Melissa Chenard, et al.
Journal of Medicinal Chemistry|February 6, 2013
Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-MetAlan B Northrup, Matthew H Katcher, Michael D Altman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaksDiane Palmieri, Paul R Lockman, Fancy C Thomas, et al.
Journal of Medicinal Chemistry|May 26, 2011
Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancerJason D Katz, James P Jewell, David J Guerin, et al.
Pageof 3